Flunarizine for Treatment Resistant Absence Epilepsy

Summary

This is an open-label, single-centre study to evaluate the clinical efficacy, safety and tolerability of Flunarizine administered as adjunctive treatment in participants diagnosed with treatment resistant absence epilepsy. The study goal is to see how efficient and safe flunarizine is at decreasing the frequency of absence seizures in children with treatment-resistant refractory epilepsy at doses of 5mg and 10mg once daily.

Timeline

Start

2019-09-20

Primary completion

2023-05-26

Completion

2023-05-26

Outcome

Outcome not reported

Stopped (Enrollment): “The enrollment wasn't as predicted. We didn't have enough numbers to show statistical significance.”

Drugs

Indications